Sapphire develops promising small-molecule ghrelin mimetics to treat metabolic, oncologic, and gastrointestinal diseases for which existing therapies are limited or marginally effective. The company's pipeline consists of first-in-class, composition-of-matter protected compounds acting within the ghrelin pathway.

For more information, please visit